Fate Therapeutics (FATE) Insider Trading & Ownership $2.02 -0.06 (-2.88%) (As of 11/15/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Fate Therapeutics (NASDAQ:FATE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.00%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$166,023.60Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$202,409.98 Get FATE Insider Trade Alerts Want to know when executives and insiders are buying or selling Fate Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address FATE Insider Buying and Selling by Quarter Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Fate Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/6/2024Yuan XuDirectorSell633$4.23$2,677.59 1/29/2024Edward J Dulac IIICFOSell1,849$5.00$9,245.00 1/9/2024Bahram ValamehrInsiderSell11,271$4.38$49,366.98 1/9/2024Cindy TahlGeneral CounselSell10,874$4.37$47,519.38 1/9/2024Edward J Dulac IIICFOSell7,028$4.37$30,712.36 1/9/2024J Scott WolchkoCEOSell14,391$4.37$62,888.67 12/26/2023Redmile Group, LlcDirectorBuy44,630$3.72$166,023.60 (Data available from 1/1/2013 forward) FATE Insider Trading Activity - Frequently Asked Questions Who is on Fate Therapeutics's Insider Roster? The list of insiders at Fate Therapeutics includes Bahram Valamehr, Brian T Powl, Cindy Tahl, Edward J Dulac III, J Scott Wolchko, John Mendlein, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu, and Yu-Waye Chu. Learn more on insiders at FATE. What percentage of Fate Therapeutics stock is owned by insiders? 5.00% of Fate Therapeutics stock is owned by insiders. Learn more on FATE's insider holdings. Which Fate Therapeutics insiders have been buying company stock? The following insiders have purchased FATE shares in the last 24 months: John Mendlein ($698,138.49), and Redmile Group, Llc ($440,023.60). How much insider buying is happening at Fate Therapeutics? Insiders have purchased a total of 215,009 FATE shares in the last 24 months for a total of $1,138,162.09 bought. Which Fate Therapeutics insiders have been selling company stock? The following insiders have sold FATE shares in the last 24 months: Bahram Valamehr ($106,572.06), Brian T Powl ($18,768.98), Cindy Tahl ($108,057.10), Edward J Dulac III ($116,611.26), J Scott Wolchko ($303,441.35), Yuan Xu ($24,329.11), and Yu-Waye Chu ($16,635.24). How much insider selling is happening at Fate Therapeutics? Insiders have sold a total of 142,132 Fate Therapeutics shares in the last 24 months for a total of $694,415.10 sold. Fate Therapeutics Key ExecutivesMr. J. Scott Wolchko (Age 54)Founder, CEO, President & Director Compensation: $920.4kMr. Edward J. Dulac III (Age 48)Chief Financial Officer Compensation: $612.5kMs. Cindy R. Tahl J.D. (Age 51)General Counsel, Corporate Secretary & Compliance Officer Compensation: $612.5kDr. Bahram Valamehr Ph.D. (Age 47)Chief Research & Development Officer Compensation: $644.5kMr. Jim Beitel M.B.A.Senior Vice President of Corporate DevelopmentDr. Jerome Bressi Ph.D.Senior Vice President of Regulatory & QualityDr. Barbara HickingbottomSenior VP of Clinical Development More Insider Trading Tools from MarketBeat Related Companies Adaptimmune Therapeutics Insider Selling bluebird bio Insider Selling Atara Biotherapeutics Insider Selling Allogene Therapeutics Insider Selling Septerna Insider Selling Collegium Pharmaceutical Insider Selling 89bio Insider Selling CARGO Therapeutics Insider Selling Phathom Pharmaceuticals Insider Selling Rapport Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:FATE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
